Download Files:
Nintedanib-d8
SKU
HY-50904S2-1mg
Category Isotope-Labeled Compounds
Tags Cancer, FGFR;Isotope-Labeled Compounds;PDGFR;VEGFR, Others;Protein Tyrosine Kinase/RTK
Products Details
Product Description
– Nintedanib-d8 is deuterium labeled Nintedanib. Nintedanib (BIBF 1120) is a potent triple angiokinase inhibitor for VEGFR1/2/3, FGFR1/2/3 and PDGFRα/β with IC50s of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59 nM/65 nM, respectively.
Web ID
– HY-50904S2
Shipping
– Room temperature
Applications
– Cancer-Kinase/protease
Molecular Formula
– C31H25D8N5O4
References
– [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.|[2]Hilberg F, et al. BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res, 2008, 68(12), 4774-4782.|[3]Roth GJ, et al. Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120). J Med Chem, 2009, 52(14), 4466-4480.
CAS Number
– 1624587-87-6
Molecular Weight
– 547.67
SMILES
– CN(C([2H])([2H])C1([2H])[2H])C([2H])([2H])C([2H])([2H])N1CC(N(C)C(C=C2)=CC=C2N/C(C3=CC=CC=C3)=C4C5=CC=C(C(OC)=O)C=C5NC/4=O)=O
Clinical Information
– No Development Reported
Research Area
– Cancer
Solubility
– 10 mM in DMSO
Target
– FGFR;Isotope-Labeled Compounds;PDGFR;VEGFR
Pathway
– Others;Protein Tyrosine Kinase/RTK
Product type
– Isotope-Labeled Compounds
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.